Istodax 10mg (Romidepsin Vials) 10mg

Istodax 10mg (romidepsin) is a prescription medication used for certain blood cancers. This vial form contains 10mg of the active ingredient romidepsin. It is designed for intravenous administration under medical supervision. Always consult a healthcare provider for proper use.

Strength

10mg

Manufacturer / TM Owner

Celgene

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Romidepsin is prescribed to treat specific types of T-cell lymphomas, including cutaneous and peripheral T-cell lymphoma. It works by interfering with cancer cell growth. Patients often ask, 'what is romidepsin used for' when prescribed this therapy. The medication targets relapsed or refractory cases where other treatments have not been effective.

Side Effects

Romidepsin may help reduce symptoms associated with blood cancers by slowing the progression of abnormal cells. Patients may experience changes in blood cell counts during treatment. Regular monitoring is typically required to assess response and manage potential effects.

Precautions & Warnings

This medication is administered by a healthcare professional in a clinical setting. Patients should inform their doctor about all current medications and medical conditions before starting romidepsin. Pregnant or breastfeeding individuals should discuss risks with their healthcare provider.

Avoid Interactions

Romidepsin can interact with other drugs, including CYP3A4 inhibitors and inducers, which may affect its effectiveness. Grapefruit products should be avoided during treatment. Patients should review all medications with their doctor to minimize interaction risks.

References

Frequently Asked Questions

Romidepsin is used to treat certain types of T-cell lymphomas, including cutaneous and peripheral T-cell lymphoma.

Romidepsin is given as an intravenous infusion by a healthcare professional in a clinical setting.

Common side effects may include nausea, fatigue, and changes in blood cell counts. Regular monitoring is recommended.

Romidepsin may harm an unborn baby. Discuss pregnancy risks and contraception options with your doctor before starting treatment.

Yes, romidepsin can interact with CYP3A4 inhibitors and inducers, as well as grapefruit products. Always inform your doctor about all medications you are taking.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.